Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy

[1]  T. Craig,et al.  Drug-Induced Severe Cutaneous Adverse Reactions (SCARs): Determine the Cause and Prevention. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  Y. Kupfer,et al.  Allopurinol‐Induced Stevens‐Johnson Syndrome , 2019, The American journal of the medical sciences.

[3]  G. Trifirò,et al.  Gender Differences in Outpatient Pediatric Drug Utilization: A Cohort Study From Southern Italy , 2019, Front. Pharmacol..

[4]  Li Zhou,et al.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. , 2019, The journal of allergy and clinical immunology. In practice.

[5]  L. Lerman,et al.  Impact of Serum Uric Acid Levels on Outcomes following Renal Artery Revascularization in Patients with Renovascular Disease , 2019, International journal of hypertension.

[6]  Hye‐Ryun Kang,et al.  Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea , 2019, Yonsei medical journal.

[7]  E. Ramírez,et al.  Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study , 2018, European Journal of Clinical Pharmacology.

[8]  C. Scavone,et al.  Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization’s Reporting? A Pharmacovigilance Study in Southern Italy , 2018, Front. Pharmacol..

[9]  H. Bagheri,et al.  Drug‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis , 2018, Journal of clinical pharmacy and therapeutics.

[10]  Sindy Hu,et al.  The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China , 2018, Journal of immunology research.

[11]  P. Whincup,et al.  Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study , 2018, International journal of cardiology.

[12]  J. Mira,et al.  Inappropriate Use of Medication by Elderly, Polymedicated, or Multipathological Patients with Chronic Diseases , 2018, International journal of environmental research and public health.

[13]  T. Harr,et al.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , 2018, Clinical Reviews in Allergy & Immunology.

[14]  L. Delgado,et al.  Stevens–Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database , 2018, Clinical and Translational Allergy.

[15]  L. Berrino,et al.  Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study , 2017, Front. Pharmacol..

[16]  L. Göttems,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals* , 2017, Anais brasileiros de dermatologia.

[17]  Faisal Inayat,et al.  Allopurinol-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Cause of Acalculous Cholecystitis? , 2017, Cureus.

[18]  O. Arasteh,et al.  Exacerbation of allopurinol‐induced drug reaction with eosinophilia and systemic symptoms by teicoplanin: A case report , 2017, Journal of clinical pharmacy and therapeutics.

[19]  M. E. Ramirez,et al.  Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review , 2017, Journal of advanced research.

[20]  E. Phillips,et al.  Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. , 2017, The journal of allergy and clinical immunology. In practice.

[21]  Afonso Cavaco,et al.  The value of patient reporting to the pharmacovigilance system: a systematic review , 2017, British journal of clinical pharmacology.

[22]  Y. Lien,et al.  Cross-Reactions Between Allopurinol and Febuxostat. , 2017, The American journal of medicine.

[23]  C. Scavone,et al.  No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region , 2016, Expert opinion on drug safety.

[24]  A. Tzankov,et al.  Drug Reaction, Eosinophilia, and Systemic Symptoms (DRESS) syndrome associated with allopurinol leading to acute necrotizing eosinophilic myocarditis and death due to papillary muscle rupture. , 2016, The journal of allergy and clinical immunology. In practice.

[25]  F. Haramburu,et al.  Risk assessment of drug‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French Pharmacovigilance Database , 2016, The British journal of dermatology.

[26]  H. Hmouda,et al.  Drug-induced hyperuricaemia and gout. , 2016, Rheumatology.

[27]  J. Wang,et al.  Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta‐Analysis , 2016, Journal of clinical hypertension.

[28]  R. Day,et al.  Allopurinol hypersensitivity: investigating the cause and minimizing the risk , 2016, Nature Reviews Rheumatology.

[29]  T. Erdem,et al.  DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine , 2016, BMJ Case Reports.

[30]  L. Naldi,et al.  Incidence, causative factors and mortality rates of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry , 2016, Pharmacoepidemiology and drug safety.

[31]  N. Shear,et al.  Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update , 2015, American Journal of Clinical Dermatology.

[32]  Jessica N. Heck,et al.  Fatal Stevens–Johnson syndrome/toxic epidermal necrolysis induced by allopurinol–rituximab–bendamustine therapy , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[33]  Chun-Ying Wu,et al.  Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. , 2015, JAMA internal medicine.

[34]  A. Rotondo,et al.  Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance , 2015, Expert opinion on drug safety.

[35]  L. Medenica,et al.  Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience , 2015, International journal of dermatology.

[36]  M. Mockenhaupt,et al.  Severe drug‐induced skin reactions: clinical features, diagnosis, etiology, and therapy , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[37]  L. Losappio,et al.  Levofloxacin induced Stevens-Johnson syndrome/ toxic epidermal necrolysis overlap syndrome: case reports , 2014, Clinical and Translational Allergy.

[38]  E. Clementi,et al.  Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment. , 2014, JAMA internal medicine.

[39]  M. Aihara,et al.  A case of toxic epidermal necrolysis induced by allopurinol with human herpesvirus-6 reactivation. , 2013, Acta dermato-venereologica.

[40]  R. Day,et al.  Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012 , 2013, Drug Safety.

[41]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[42]  D. Margolis,et al.  Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population‐Based Cohort Study , 2013, Arthritis care & research.

[43]  Somchai Yongsiri,et al.  Characteristics of toxic epidermal necrolysis and Stevens-Johnson syndrome: a 5-year retrospective study. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[44]  C. Ferreli,et al.  Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department – Cagliari University (Italy) , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[45]  Hyon K. Choi,et al.  Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study , 2012, BMJ : British Medical Journal.

[46]  M. Mockenhaupt.  The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2011, Expert review of clinical immunology.

[47]  R. Kumari,et al.  Drug hypersensitivity syndrome. , 2011, Indian journal of dermatology, venereology and leprology.

[48]  J. Roujeau,et al.  The DRESS syndrome: a literature review. , 2011, The American journal of medicine.

[49]  B. Thong,et al.  Epidemiology and risk factors for drug allergy. , 2011, British journal of clinical pharmacology.

[50]  L. French,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome , 2010, Orphanet journal of rare diseases.

[51]  T. Mersfelder,et al.  Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[52]  T. Kuo,et al.  Clinicopathlogical features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[53]  H. Y. Lee,et al.  Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? , 2008, Singapore medical journal.

[54]  R. Zhao,et al.  Severe Epidermal Necrolysis after Bortezomib Treatment for Multiple Myeloma , 2007, Acta Haematologica.

[55]  P. Simkin,et al.  Epidemiology of hyperuricemia and gout. , 2005, The American journal of managed care.

[56]  E. Ruocco,et al.  Lyell's syndrome. , 2005, Skinmed.

[57]  R. Pwu,et al.  Risk estimates for drugs suspected of being associated with Stevens‐Johnson syndrome and toxic epidermal necrolysis: a case‐control study , 2005, Internal medicine journal.

[58]  V. Sehgal,et al.  Toxic epidermal necrolysis (TEN) Lyell's syndrome , 2005, The Journal of dermatological treatment.

[59]  S. Daskalopoulou,et al.  The impact of serum uric acid on cardiovascular outcomes in the LIFE study. , 2004, Kidney international.

[60]  A. J. Reyes.  Cardiovascular Drugs and Serum Uric Acid , 2003, Cardiovascular Drugs and Therapy.

[61]  S. Taş,et al.  Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update , 2003, Dermatology.

[62]  A. Sidoroff,et al.  Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis , 2000, American journal of clinical dermatology.

[63]  M. Mockenhaupt,et al.  Epidemiology of drug-induced severe skin reactions. , 1996, Seminars in cutaneous medicine and surgery.

[64]  F. Oehme.  Goodman and Gilman 's: The pharmacological basis of therapeutics , 1996 .

[65]  J. Sacristán,et al.  Allopurinol Hypersensitivity Syndrome: A Review , 1993, The Annals of pharmacotherapy.

[66]  B. Strom,et al.  A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. , 1991, Archives of dermatology.

[67]  D. Pennell,et al.  FATAL STEVENS-JOHNSON SYNDROME IN A PATIENT ON CAPTOPRIL AND ALLOPURINOL , 1984, The Lancet.

[68]  A. Prasad,et al.  Letter: Zinc deficiency in man. , 1974 .

[69]  G. Manso,et al.  Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs. , 2015, European review for medical and pharmacological sciences.

[70]  E. Jeziorski,et al.  [DRESS syndrome]. , 2015, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[71]  V. Descamps,et al.  DRESS syndrome. , 2014, Joint, bone, spine : revue du rhumatisme.

[72]  H. Ranu,et al.  A CASE SERIES OF ALLOPURINOL-INDUCED TOXIC EPIDERMAL NECROLYSIS , 2011, Indian journal of dermatology.

[73]  T. Yeh,et al.  Allopurinol in Dermatology , 2010, American journal of clinical dermatology.

[74]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[75]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[76]  J. Roujeau,et al.  Drug-Induced Skin, Nail and Hair Disorders , 2007, Drug safety.

[77]  B. Delgrange,et al.  [Fatal toxic epidermolysis following administration of allopurinol]. , 1989, Acta clinica Belgica.